‌Welcome to Sinoway Industry co., ltd. 's booth 6E31at CPhI Japan 2025!‌ We are thrilled to invite you to Sinoway's ‌Booth 6E31‌ to explore our cutting-edge solutions in ‌APIs‌, ‌pharmaceutical intermediates‌ and alongside our tailored ‌CDMO services‌‌. With over 30 years of expertise in global phar...

Peptides are unique pharmaceutical compounds that play vital roles in physiological processes, including hormones and neurotransmitters. Peptide drugs, known for their good druggability, high activity, low toxicity, and minimal drug interactions, generated global sales of $22 billion in 2015, making...

On April 5, 2024, a study from a Swedish university revealed a new class of antibiotics effective against multidrug-resistant bacteria, showing promise in treating bloodstream infections in mice. Published in *Proceedings of the National Academy of Sciences*, the discovery is significant due to the ...

In recent years, the pharmaceutical industry has witnessed a surge in interest and investment in antibody-drug conjugates (ADCs), a class of targeted therapies that combine the specificity of antibodies with the cytotoxic potency of drugs. This trend is evident in the increasing heat on ADC pipeline...

The 91st API China successfully open in Xi'an in Oct. 16th, 2024. This exhibition brought together numerous Chinese and international pharmaceutical companies, showcasing the latest products and technologies of pharmaceutical&healthcare industry. It covered multiple fields including pharmaceutic...

CPHI Milan 2024 was held successfully in Oct. 8th-10th, 2024. As a exhibitor for more than 20 years, Sinoway Industrial co., ltd. attended this event and our booth number is 5D94.  Sinoway is a professional company, which is consistently bridging cutting-edge technology and ...

Warmly welcome you to visit Sinoway booth 5D94 at CPhI Milan 2024 from Oct. 8th to 10th. What Sinoway can do for you? 1 Up-to-date market information and recommendations based on the connection for 37years in pharmaceutical industry 2. High quality and moderate price of Key intermediates for generic...